Literature DB >> 24401082

Indirubin 3'-monoxime, from a Chinese traditional herbal formula, suppresses viremia in humanized mice infected with multidrug-resistant HIV.

Alonso Heredia1, Senthilkumar Natesan, Nhut M Le, Sandra Medina-Moreno, Juan C Zapata, Marvin Reitz, Joseph Bryant, Robert R Redfield.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24401082      PMCID： PMC4010160          DOI： 10.1089/aid.2013.0249

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


× No keyword cloud information.
  27 in total

1.  Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product.

Authors:  S Y Kao; A F Calman; P A Luciw; B M Peterlin
Journal:  Nature       Date:  1987 Dec 3-9       Impact factor: 49.962

Review 2.  Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China.

Authors:  Zhijian Xiao; Yushu Hao; Bingcheng Liu; Lingsheng Qian
Journal:  Leuk Lymphoma       Date:  2002-09

3.  Flavopiridol inhibits P-TEFb and blocks HIV-1 replication.

Authors:  S H Chao; K Fujinaga; J E Marion; R Taube; E A Sausville; A M Senderowicz; B M Peterlin; D H Price
Journal:  J Biol Chem       Date:  2000-09-15       Impact factor: 5.157

4.  Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases.

Authors:  R Hoessel; S Leclerc; J A Endicott; M E Nobel; A Lawrie; P Tunnah; M Leost; E Damiens; D Marie; D Marko; E Niederberger; W Tang; G Eisenbrand; L Meijer
Journal:  Nat Cell Biol       Date:  1999-05       Impact factor: 28.824

5.  Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

Authors:  N K Back; M Nijhuis; W Keulen; C A Boucher; B O Oude Essink; A B van Kuilenburg; A H van Gennip; B Berkhout
Journal:  EMBO J       Date:  1996-08-01       Impact factor: 11.598

6.  Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication.

Authors:  Akbar Ali; Animesh Ghosh; Robin S Nathans; Natalia Sharova; Siobhan O'Brien; Hong Cao; Mario Stevenson; Tariq M Rana
Journal:  Chembiochem       Date:  2009-08-17       Impact factor: 3.164

7.  Effect of mimetic CDK9 inhibitors on HIV-1-activated transcription.

Authors:  Rachel Van Duyne; Irene Guendel; Elizabeth Jaworski; Gavin Sampey; Zachary Klase; Hao Chen; Chen Zeng; Dmytro Kovalskyy; Mahmoud H El Kouni; Benjamin Lepene; Alexis Patanarut; Sergei Nekhai; David H Price; Fatah Kashanchi
Journal:  J Mol Biol       Date:  2012-12-13       Impact factor: 5.469

8.  Crystal structure of HIV-1 Tat complexed with human P-TEFb.

Authors:  Tahir H Tahirov; Nigar D Babayeva; Katayoun Varzavand; Jeffrey J Cooper; Stanley C Sedore; David H Price
Journal:  Nature       Date:  2010-06-10       Impact factor: 49.962

9.  HIV-1 tat protein stimulates transcription by binding to a U-rich bulge in the stem of the TAR RNA structure.

Authors:  C Dingwall; I Ernberg; M J Gait; S M Green; S Heaphy; J Karn; A D Lowe; M Singh; M A Skinner
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

10.  HIV-1 Tat protein promotes formation of more-processive elongation complexes.

Authors:  R A Marciniak; P A Sharp
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598
View more
  8 in total

Review 1.  Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors.

Authors:  Maxime J Jean; Guillaume Fiches; Tsuyoshi Hayashi; Jian Zhu
Journal:  AIDS Res Hum Retroviruses       Date:  2018-12-12       Impact factor: 2.205

2.  Full Length Single Chain Fc Protein (FLSC IgG1) as a Potent Antiviral Therapy Candidate: Implications for In Vivo Studies.

Authors:  Olga S Latinovic; Sandra Medina-Moreno; Kate Schneider; Neelakshi Gohain; Juan Zapata; Marzena Pazgier; Marvin Reitz; Joseph Bryant; Robert R Redfield
Journal:  AIDS Res Hum Retroviruses       Date:  2015-06-22       Impact factor: 2.205

Review 3.  Targeting HIV transcription: the quest for a functional cure.

Authors:  Guillaume Mousseau; Sonia Mediouni; Susana T Valente
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

Review 4.  Cure and Long-Term Remission Strategies.

Authors:  Luisa Mori; Susana T Valente
Journal:  Methods Mol Biol       Date:  2022

5.  Adoptive transfer of aminobisphonate-expanded Vγ9Vδ2+ T cells does not control HIV replication in a humanized mouse model.

Authors:  Bhawna Poonia
Journal:  Immunotherapy       Date:  2016-05       Impact factor: 4.196

6.  Targeting of CDK9 with indirubin 3'-monoxime safely and durably reduces HIV viremia in chronically infected humanized mice.

Authors:  Sandra Medina-Moreno; Thomas C Dowling; Juan C Zapata; Nhut M Le; Edward Sausville; Joseph Bryant; Robert R Redfield; Alonso Heredia
Journal:  PLoS One       Date:  2017-08-17       Impact factor: 3.240

7.  Aikeqing decreases viral loads in SHIV89.6-infected Chinese rhesus macaques.

Authors:  Gao-Hong Zhang; Jian-Bao Han; Lin Zhu; Rong-Hua Luo; Xi-He Zhang; Xin Chen; Ying-Jie Hu; Lin-Chun Fu; Yong-Tang Zheng
Journal:  Chin Med       Date:  2016-07-01       Impact factor: 5.455

8.  Indirubin derivatives are potent and selective anti-Trypanosoma cruzi agents.

Authors:  Antonia Efstathiou; Cássio Santana Meira; Nicolas Gaboriaud-Kolar; Tanira Matutino Bastos; Vinícius Pinto Costa Rocha; Konstantina Vougogiannopoulou; Alexios-Leandros Skaltsounis; Despina Smirlis; Milena Botelho Pereira Soares
Journal:  Virulence       Date:  2018       Impact factor: 5.882
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.